Pharmaceutica Analytica Acta

Department of Applied Pharmacy and Pharmacokinetics, University of Alberta, Edmonton, Alberta, Canada

Biography

Dr. Ryosaku Ota is a distinguished researcher and academic in the field of pharmaceutical sciences, with a focus on pharmacokinetics and drug development. He is currently affiliated with the Department of Applied Pharmacy and Pharmacokinetics at the University of Alberta in Canada. His research primarily addresses the challenges faced in the development of orphan drugs, which are critical for treating rare diseases that affect small patient populations.

Dr. Ota has contributed extensively to the understanding of drug mechanisms and efficacy in rare disease contexts, with a particular emphasis on how orphan medications can meet the unmet needs of patients with rare and serious illnesses. His work includes a detailed exploration of the role of orphan drugs in modern pharmacology, considering both scientific and regulatory aspects?

Furthermore, Dr. Ota has co-authored studies on the pharmacological implications of various gene mutations, including those linked to conditions like catecholaminergic polymorphic ventricular tachycardia (CPVT)?

His publications reflect his commitment to advancing therapeutic strategies through improved drug delivery systems and innovative research techniques in pharmacokinetics.

Publications

• Commentary Article   
  Orphan Drugs and Rare Diseases: Overcoming the Challenges in Pharma
  Author(s): Ryosaku Ota*
  
  

  DOI: 10.35248/2153-2435.24.15.783

  HTML PDF

Other relevant publications from this author

• 1. Cytosolic Ca2+-dependent Ca2+ release activity primarily determines the ER Ca2+ level in cells expressing the CPVT-linked mutant RYR2

  2. Various Research Papers on Gene Mutations in Orphan Diseases